Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of PQ912 in early Alzheimer's disease
CTR20221001Phase 2Active
- Sponsor
- Vivoryon Therapeutics N.V.
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of varoglutamstat in Alzheimer's disease (AD), sponsored by Vivoryon Therapeutics N.V. Started Apr 2022; status: active.
02
Drugs
varoglutamstat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20221001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221001.